About Cyprotex
Cyprotex PLC, together with its subsidiaries, provides in vitro and in silico absorption, distribution, metabolism, excretion, toxicity, and pharmacokinetics (ADMET and PK) services in North America, Mainland Europe, and the United Kingdom. Its ADME and PK services include in vitro metabolism, in vitro permeability, physicochemical properties, bioanalysis, protein binding, and prodrug services; and toxicology services comprise multiparametric toxicity, cardiotoxicity, customised toxicology services, 3D microtissue hepatotoxicity services, mechanistic toxicity services, in vitro drug-drug interaction assays, and genotoxicity assays. The company also provides Cloe PK, a software system that uses physiologically based pharmacokinetic in silico modeling for pharmacokinetic simulation; Cloe HIA, a physiological model for the prediction of human intestinal absorption; Cyprotex Discovery Bus, a software platform to enhance drug discovery; and various in vitro safety testing services for pharmaceutical companies developing topical therapeutics, and for the cosmetics and consumer-products industries. In addition, it offers integrated drug discovery services comprising medicinal chemistry, synthetic chemistry, computational chemistry, bioscience, arrays and libraries, and process and scale-up chemistry; and physicochemical profiling services for measurement of pKa, logP/logD, solubility, and dissolution in aqueous, solvent, biorelevant media, and in the presence of formulation additives. Cyprotex PLC has collaboration with Sygnature Discovery Limited, Sirius Analytical Limited, and Pfizer. It serves various industries, including pharmaceutical, biotechnology, cosmetic, personal care, agrochemical, chemical industries, and academia. The company was founded in 1999 and is headquartered in Macclesfield, the United Kingdom.
